Innovative trial design may have cost Lilly’s Donanemab accelerated approvalTherapeuticsThe FDA issued a complete response letter refusing accelerated approval for Eli Lilly’s Alzheimer’s disease candidate donanemab, the Indianapolis-based company announced yesterday. Read more January 20, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/02/FDAs-ODAC-Says-Lilly-Innovent-Must-Run-U.S.-Trial-BioSpace-2-10-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-01-20 09:10:352023-01-20 09:16:32Innovative trial design may have cost Lilly’s Donanemab accelerated approval
